info_outline
Food for Thought: Should the FDA, EMA, NCI, NHLBI, ICOS, ACC, AHA, mandate Cardio-Oncologists on Cancer Clinical Trials with Cardiotoxic Drugs?| Trastuzumab Cardiotoxicity in DESTINY-Breast04 Trial
04/24/2024
Food for Thought: Should the FDA, EMA, NCI, NHLBI, ICOS, ACC, AHA, mandate Cardio-Oncologists on Cancer Clinical Trials with Cardiotoxic Drugs?| Trastuzumab Cardiotoxicity in DESTINY-Breast04 Trial
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2203690#.YsoGdaAS_fY.twitter DESTINY-Changing Results for Advanced Breast Cancer | NEJM Early Detection and Monitoring of Vulnerable Myocardium in Patients Receiving Chemotherapy: Is It Time to Change Tracks? https://www.heartfailure.theclinics.com/article/S1551-7136(11)00037-7/fulltext#.YsoHTLcs3-M.twitter Using a Magnet to Strike Gold https://www.heartfailure.theclinics.com/article/S1551-7136(09)00026-9/fulltext#.YsoG3Cq5rAs.twitter
/episode/index/show/drbaligasinternalmedicinepodcasts/id/23694932
